Table 5 Site-specific efficacy of ceCT and 18F-FDG PET/CT
Site | Â | ceCT | PET/CT | Combination of ceCT and PET/CT | p -value | |
|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | ceCT vs PET/CT | ceCT vs Combination |
| Â | Sensitivity* | 88% (14/16) | 88% (14/16) | 100% (16/16) | 0.10 | 0.5 |
Locoregional area (n = 16) | Specificity* | 86% (37/43) | 93% (40/43) | 84% (36/43) | 0.38 | 1.0 |
| Â | PPV | 70% (14/20) | 82% (14/17) | 70% (16/23) | 0.46 | 1.0 |
| Â | NPV | 95% (37/39) | 93% (40/42) | 100% (36/36) | 1.0 | 0.49 |
| Â | Sensitivity* | 63% (10/16) | 94% (15/16) | 94% (15/16) | 0.08 | 0.08 |
Lymph node (n = 16) | Specificity* | 93% (40/43) | 95% (41/43) | 91% (39/43) | 0.91 | 0.74 |
| Â | PPV | 77% (10/13) | 88% (15/17) | 79% (15/19) | 0.63 | 0.61 |
| Â | NPV | 87% (40/46) | 98% (41/43) | 98% (39/40) | 0.11 | 0.12 |